NCT05813743

Detection of Urinary Bladder Wall Involvement in Abnormally Invasive Placenta (AIP) by 3D Ultrasonography

Completed NA Last updated 30 August 2023

What this trial tests

NA trial testing 3 dimensional ultrasound in Placenta Accreta in 52 participants. Completed in 1 August 2023.

Timeline

1 November 2022

Primary endpoint
15 July 2023

1 August 2023

Quick facts

Lead sponsor	Cairo University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	52
Start date	1 November 2022
Primary completion	15 July 2023
Estimated completion	1 August 2023
Sites	1 location across Egypt

Drugs / interventions tested

• 3 dimensional ultrasound

Conditions studied

• Placenta Accreta — all drugs for Placenta Accreta →

Sponsor

Cairo University

Who can join

Eligibility, female only, with Placenta Accreta. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the last three decades , the raise in cesarean delivery rates has led to a massive increase in the incidence of the abnormally invasive placenta .Complete separation of the abnormally invasive placenta is very difficult and usually fails and this may leads to life threatening hemorrhage and other morbidities e.g injury of the urinary tract.

Antenatal diagnosis of the extent of the myometrial involvement may help in the anticipation and the planning of management eg: to proceed a conservative management or cesarean hysterectomy in case of extensive myometrial involvement . Three dimensional (3D) power Doppler ultrasound now represents a turning point for diagnosis the abnormal placentation .

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.